<DOC>
	<DOCNO>NCT00605098</DOCNO>
	<brief_summary>This multicenter , open , prospective randomize study aim evaluate pharmacokinetics tablet formulation lopinavir/r administer combination two nucleoside analog HIV-infected pregnant woman two different dosage : - Group 1 ( standard dosage ) : 200/50 mg lopinavir/r , 2 tablet every 12 hour , plus two nucleoside analog . - Group 2 ( increase dosage ) : 200/50 mg lopinavir/r , 2 tablet every 12 hour end second trimester gestation ( 24 week ) 3 tablet every 12 hour third trimester ( 25 week ) , plus two nucleoside analog . Treatment initiate time 14 30 week gestation maintain least 6 week delivery . The objective : - To compare pharmacokinetic parameter standard increase dosage tablet formulation lopinavir/r pregnancy . - To determine whether standard and/or increase dosage tablet formulation lopinavir/r pregnancy confers exposure drug observe woman end pregnancy historic control . - To evaluate transplacental passage lopinavir/r base ratio serum concentration maternal blood time delivery cord blood two drug dosage ( standard increase ) administer pregnancy . - To evaluate tolerability two lopinavir/r dosage ( standard increase ) pregnancy . - To describe vertical transmission rate HIV child pregnant woman include study .</brief_summary>
	<brief_title>Pharmacokinetics Tablet Formulation Lopinavir/r Standard Increased Dosage During Pregnancy</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Capacity consent wish participate study , document sign specific informed consent form ( ICF ) study . Age 18 year old . Pregnancy document urine blood examination ultrasound . Gestational age 14 30 week calculate ultrasound , obstetric examination date last menstruation , depend consider exact medical investigator . HIV infection document two serological test use different method analysis HIV viral load positive result . No use antiretroviral drug time diagnosis pregnancy ( previous prophylaxis treatment allow ) . Intention continue treatment study least 6 week delivery . History hypersensitivity lopinavir ritonavir . Need concomitant use contraindicate drug combination lopinavir/ritonavir . Any condition , opinion medical researcher , impairs participation fulfillment procedure study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Vertical disease transmission</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>HIV seronegativity</keyword>
</DOC>